Table 1.
Baseline characteristics
| Features | Overall n = 26 (%) | Primary (n = 13) | Secondary (n = 13) |
|---|---|---|---|
| Age | |||
| Median | 59.5 y | 51 y | 62 y |
| Range | 26‐78 y | 26‐78 y | 34‐77 y |
| Sex | |||
| Female | 16 (62) | 9 | 7 |
| Male | 10 (38) | 4 | 6 |
| ECOG | |||
| 0 | 16 (62) | 9 | 7 |
| 1 | 7 (27) | 3 | 4 |
| 2 | 1 (4) | 1 | 0 |
| 3 | 2 (8) | 0 | 2 |
| Stage at original MZL diagnosis | |||
| I | 12 (46) | 11 | 1 |
| II | 2 (8) | 1 | 1 |
| III | 0 | 0 | 0 |
| IV | 12 (46) | 1 | 11 |
| B symptoms | |||
| Present | 2 (8) | 0 | 2 |
| Absent | 23 (88) | 13 | 10 |
| Missing | 1 (4) | 0 | 1 |
| CNS location | |||
| Dural only | 13 (50) | 9 | 4 |
| Parenchymal only | 5 (19) | 3 | 2 |
| Leptomeningeal only | 1 (4) | 0 | 1 |
| Other | 3 (12) | 0 | 3 |
| Missing | 4 (15) | 1 | 3 |
| Serum LDH | |||
| Normal | 16 (62) | 9 | 7 |
| Elevated | 7 (27) | 3 | 4 |
| Missing | 3 (12) | 1 | 2 |
| Treatment | |||
| RTx alone | 1 (4) | 0 | 1 |
| CTx alone | 5 (19) | 0 | 5 |
| SX + RTx | 7 (27) | 5 | 2 |
| SX + CTx | 6 (23) | 4 | 2 |
| RTx + CTx | 0 | 0 | 0 |
| SX + RTx +CTx | 4 (15) | 3 | 1 |
| Missing | 3 (12) | 1 | 2 |
| PF event | |||
| No | 13 (50) | 11 | 2 |
| Yes | 10 (38) | 2 | 8 |
| Missing | 3 (12) | 0 | 3 |
| Outcome | |||
| Alive | 22 (85) | 13 | 9 |
| Dead | 4 (15) | 0 | 4 |
Data expressed as number (percentage).
Abbreviations: CTx, chemotherapy; LDH, lactate dehydrogenase; PF, progression free; RTx, radiotherapy; SX, surgery.